Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin therapy with a non-negligible incidence (estimated at 2.6% of unfractionated heparin treatments and 0.2% of low molecular weight heparin treatments). It is generally secondary to the appearance of IgG antibodies directed against the platelet factor 4 (PF4) - heparin complex. These antibodies, once bound to this complex, are likely to activate platelets: the thrombotic risk generated can be potentially fatal.
Study Type
OBSERVATIONAL
Enrollment
894
Laboratoire d'Hématologie - CHU de Strasbourg - France
Strasbourg, France
RECRUITINGRetrospective description of the biological diagnosis approach for heparin-induced thrombocytopenia (HIT) in the Hematology laboratory of the University Hospitals of Strasbourg
Time frame: through study completion, an average of 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.